Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndrome

A Phase III, multicenter, randomized study to compare the rate of complete response (CR) and duration of CR, in patients with TP53-mutated MDS who will receive APR-246 and azacitidine or azacitidine alone.
Myelodysplastic Syndrome
III
Byrne, Michael
NCT03745716
VICCHEM18178

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: